Time to Harmonize Mitochondrial Syndrome Nomenclature and Classification: A Consensus from the North American Mitochondrial Disease Consortium (NAMDC)

Overview

Journal Mol Genet Metab

Specialty Endocrinology

Date 2022 May 23

PMID 35606253

Authors

Valentina Emmanuele

Jaya Ganesh

Georgirene Vladutiu

Richard Haas

Douglas Kerr

Russell P Saneto

Bruce H Cohen

Johan L K Van Hove

Fernando Scaglia

Charles Hoppel

Xiomara Q Rosales

Emanuele Barca

Richard Buchsbaum

John L Thompson

Salvatore DiMauro

Michio Hirano

Affiliations

Soon will be listed here.

Abstract

Objective: To harmonize terminology in mitochondrial medicine, we propose revised clinical criteria for primary mitochondrial syndromes.

Methods: The North American Mitochondrial Disease Consortium (NAMDC) established a Diagnostic Criteria Committee comprised of members with diverse expertise. It included clinicians, researchers, diagnostic laboratory directors, statisticians, and data managers. The Committee conducted a comprehensive literature review, an evaluation of current clinical practices and diagnostic modalities, surveys, and teleconferences to reach consensus on syndrome definitions for mitochondrial diseases. The criteria were refined after manual application to patients enrolled in the NAMDC Registry.

Results: By building upon published diagnostic criteria and integrating recent advances, NAMDC has generated updated consensus criteria for the clinical definition of classical mitochondrial syndromes.

Conclusions: Mitochondrial diseases are clinically, biochemically, and genetically heterogeneous and therefore challenging to classify and diagnose. To harmonize terminology, we propose revised criteria for the clinical definition of mitochondrial disorders. These criteria are expected to standardize the diagnosis and categorization of mitochondrial diseases, which will facilitate future natural history studies and clinical trials.

Citing Articles

Characterization of Factors Associated With Death in Deceased Patients With Mitochondrial Disorders: A Multicenter Cross-Sectional Survey.

Ivaniuk A, Anselm I, Bowen A, Cohen B, Eminoglu F, Estrella J Neurology. 2025; 104(4):e209779.

PMID: 39883904 PMC: 11781783. DOI: 10.1212/WNL.0000000000209779.

Genetic landscape of primary mitochondrial diseases in children and adults using molecular genetics and genomic investigations of mitochondrial and nuclear genome.

Ambrose A, Bahl S, Sharma S, Zhang D, Hung C, Jain-Ghai S Orphanet J Rare Dis. 2024; 19(1):424.

PMID: 39533303 PMC: 11555972. DOI: 10.1186/s13023-024-03437-x.

Multi-Allelic Mitochondrial DNA Deletions in an Adult Dog with Chronic Weakness, Exercise Intolerance and Lactic Acidemia.

Shelton G, Mickelson J, Friedenberg S, Cullen J, Mehra J, Guo L Animals (Basel). 2024; 14(13).

PMID: 38998058 PMC: 11240360. DOI: 10.3390/ani14131946.

Protein biomarkers GDF15 and FGF21 to differentiate mitochondrial hepatopathies from other pediatric liver diseases.

Van Hove J, Friederich M, Strode D, Van Hove R, Miller K, Sharma R Hepatol Commun. 2024; 8(1).

PMID: 38180987 PMC: 10781130. DOI: 10.1097/HC9.0000000000000361.

The clinical spectrum of MELAS and associated disorders across ages: a retrospective cohort study.

Cox B, Pearson J, Mandrekar J, Gavrilova R Front Neurol. 2023; 14:1298569.

PMID: 38156086 PMC: 10753009. DOI: 10.3389/fneur.2023.1298569.

References

Whittaker R, Blackwood J, Alston C, Blakely E, Elson J, McFarland R . Urine heteroplasmy is the best predictor of clinical outcome in the m.3243A>G mtDNA mutation. Neurology. 2009; 72(6):568-9. PMC: 2818183. DOI: 10.1212/01.wnl.0000342121.91336.4d. View

Tanji K, Bonilla E . Light microscopic methods to visualize mitochondria on tissue sections. Methods. 2008; 46(4):274-80. DOI: 10.1016/j.ymeth.2008.09.027. View

Semba R, Sun K, Egan J, Crasto C, Carlson O, Ferrucci L . Relationship of serum fibroblast growth factor 21 with abnormal glucose metabolism and insulin resistance: the Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab. 2012; 97(4):1375-82. PMC: 3319186. DOI: 10.1210/jc.2011-2823. View

Wong L . Next generation molecular diagnosis of mitochondrial disorders. Mitochondrion. 2013; 13(4):379-87. DOI: 10.1016/j.mito.2013.02.001. View

Gorman G, Schaefer A, Ng Y, Gomez N, Blakely E, Alston C . Prevalence of nuclear and mitochondrial DNA mutations related to adult mitochondrial disease. Ann Neurol. 2015; 77(5):753-9. PMC: 4737121. DOI: 10.1002/ana.24362. View

Heighton J, Brady L, Newman M, Tarnopolsky M . Clinical and demographic features of chronic progressive external ophthalmoplegia in a large adult-onset cohort. Mitochondrion. 2017; 44:15-19. DOI: 10.1016/j.mito.2017.12.006. View

Pitceathly R, Rahman S, Hanna M . Single deletions in mitochondrial DNA--molecular mechanisms and disease phenotypes in clinical practice. Neuromuscul Disord. 2012; 22(7):577-86. DOI: 10.1016/j.nmd.2012.03.009. View

Wortmann S, Duran M, Anikster Y, Barth P, Sperl W, Zschocke J . Inborn errors of metabolism with 3-methylglutaconic aciduria as discriminative feature: proper classification and nomenclature. J Inherit Metab Dis. 2013; 36(6):923-8. DOI: 10.1007/s10545-012-9580-0. View

Finsterer J, Zarrouk-Mahjoub S, Shoffner J . MERRF Classification: Implications for Diagnosis and Clinical Trials. Pediatr Neurol. 2018; 80:8-23. DOI: 10.1016/j.pediatrneurol.2017.12.005. View

10.

Saneto R, Friedman S, Shaw D . Neuroimaging of mitochondrial disease. Mitochondrion. 2008; 8(5-6):396-413. PMC: 2600593. DOI: 10.1016/j.mito.2008.05.003. View

11.

Phadke R . Myopathology of Adult and Paediatric Mitochondrial Diseases. J Clin Med. 2017; 6(7). PMC: 5532572. DOI: 10.3390/jcm6070064. View

12.

Morava E, van den Heuvel L, Hol F, De Vries M, Hogeveen M, Rodenburg R . Mitochondrial disease criteria: diagnostic applications in children. Neurology. 2006; 67(10):1823-6. DOI: 10.1212/01.wnl.0000244435.27645.54. View

13.

Witters P, Saada A, Honzik T, Tesarova M, Kleinle S, Horvath R . Revisiting mitochondrial diagnostic criteria in the new era of genomics. Genet Med. 2017; 20(4):444-451. DOI: 10.1038/gim.2017.125. View

14.

Cui H, Li F, Chen D, Wang G, Truong C, Enns G . Comprehensive next-generation sequence analyses of the entire mitochondrial genome reveal new insights into the molecular diagnosis of mitochondrial DNA disorders. Genet Med. 2013; 15(5):388-94. DOI: 10.1038/gim.2012.144. View

15.

Zolkipli-Cunningham Z, Xiao R, Stoddart A, McCormick E, Holberts A, Burrill N . Mitochondrial disease patient motivations and barriers to participate in clinical trials. PLoS One. 2018; 13(5):e0197513. PMC: 5957366. DOI: 10.1371/journal.pone.0197513. View

16.

DiMauro S, Schon E, Carelli V, Hirano M . The clinical maze of mitochondrial neurology. Nat Rev Neurol. 2013; 9(8):429-44. PMC: 3959773. DOI: 10.1038/nrneurol.2013.126. View

17.

Mancuso M, Orsucci D, Angelini C, Bertini E, Carelli V, Comi G . Redefining phenotypes associated with mitochondrial DNA single deletion. J Neurol. 2015; 262(5):1301-9. DOI: 10.1007/s00415-015-7710-y. View

18.

Bernier F, Boneh A, Dennett X, Chow C, Cleary M, Thorburn D . Diagnostic criteria for respiratory chain disorders in adults and children. Neurology. 2002; 59(9):1406-11. DOI: 10.1212/01.wnl.0000033795.17156.00. View

19.

Mancuso M, McFarland R, Klopstock T, Hirano M . International Workshop:: Outcome measures and clinical trial readiness in primary mitochondrial myopathies in children and adults. Consensus recommendations. 16-18 November 2016, Rome, Italy. Neuromuscul Disord. 2017; 27(12):1126-1137. PMC: 6094160. DOI: 10.1016/j.nmd.2017.08.006. View

20.

Koo B, Um S, Seo D, Joo S, Bae J, Park J . Growth differentiation factor 15 predicts advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease. Liver Int. 2017; 38(4):695-705. DOI: 10.1111/liv.13587. View